BIOCORP And NOVO NORDISK Strengthen Their Partnership With A New Settlement On Mallya® Good Sensor

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French firm specialised within the design, improvement, and manufacturing of revolutionary medical units, declares the signature of a partnership settlement with Novo Nordisk for the commercialization of Mallya, initially in Japan.

This new settlement is reinforcing the partnership between Novo Nordisk and BIOCORP targeted on improvement of the Mallya product introduced in September 2021. Whereas this primary improvement settlement was protecting manufacturers within the insulin house solely, an extra therapeutic space wherein Novo Nordisk has a presence has been included earlier this 12 months.

Mallya (a non-medical machine in Japan) is a brilliant sensor that instantly attaches to the Novo Nordisk FlexTouch^® insulin pens. Mallya will allow sufferers with diabetes utilizing FlexTouch^® pens to routinely accumulate and file every day insulin injection information such because the variety of insulin items, the date, and the time. Because of a cellular utility linked to Mallya, sufferers will be capable of observe their injection historical past and comply with their remedy in real-time. Mallya is suitable with all Novo Nordisk FlexTouch^® insulin pens.

Primarily based on the settlement, Novo Nordisk shall be commercializing Mallya in Japan from the primary half of 2023.

Kasper Bødker Mejlvang, President and Consultant Director of Novo Nordisk Pharma, concerning the settlement,

“Earlier this 12 months, we launched the primary ever sensible insulin pens^* in Japan (NovoPen^® 6 and NovoPen Echo^® Plus). Nevertheless, most of our sufferers right this moment in Japan use insulin with FlexTouch^®. As such, we’re more than happy by working with BIOCORP, which manufactures and imports Mallya, to supply digital well being to much more sufferers”

^* Good insulin pen: a generic time period for insulin pens which might routinely file insulin dosing information (time, amount) and wirelessly switch the info to cellular apps, and so on. put in in person’s smartphone¹.

“We’re very pleased with this business launch in Japan by means of our accomplice Novo Nordisk. Japan is among the many main international locations in the usage of diabetes administration units and monitoring units. It is a pure and excessive potential marketplace for Mallya. Along with that launch, we’re glad to have our relationship with Novo Nordisk being bolstered on an extra therapeutic space” stated Eric Dessertenne, CEO of BIOCORP.

¹ David C. Klonoff, MD, Good pens will enhance insulin remedy, Journal of Diabetes Science and Expertise 2018, Vol. 12(3) 551-553